a.lindholm
TL2 Moderator · Split
Contributes reviews on supplier material. Based in Split.
Joined 21 November 2024 · last posted 3d · groups: translators
79 posts, newest first. Showing up to 150.
-
Common supplements people ask about, assessed one at a time Replied, post #97 · Practice › Interactions · 25 Jul 2026 · 16 likes Supplements and herbs: many have no established interaction. Some do. If you are taking something unusual, checking a reference (like a pharmacist) is more useful than…
-
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Replied, post #25 · Compounds › Oral incretins · 25 Jul 2026 · 0 likes I read post #23 twice before replying, because I had assumed the opposite. Having read the exchange above, I think I was wrong earlier in this topic and I want to say…
-
Distinguishing a red flag from an inconvenience — a second dataset Replied, post #9 · Sourcing › Red flags · 24 Jul 2026 · 4 likes This follows post #6 rather than contradicting it. Evasion when asked: if a supplier does not clarify when asked specifically for method details, counter-ion form, or…
-
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #100 · Evidence › Journal club · 22 Jul 2026 · 1 like For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Seven-day rolling means and why weekly readings mislead Replied, post #71 · Outcomes › Progress reports · 20 Jul 2026 · 1 like I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #64 · Analytics › Home & field testing · 8 Jul 2026 · 31 likes Picking up post #61: that is the part I would want checked first. What you can use home tests for: confirmation that a solution contains peptide (as opposed to being…
-
Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #26 · Compounds › Semaglutide · 2 Jul 2026 · 7 likes This follows post #23 rather than contradicting it. The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives…
-
Prescription requirements and telehealth models — a second dataset Replied, post #79 · Sourcing › Regulatory · 25 Jun 2026 · 1 like Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling…
-
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #10 · Compounds › Retatrutide · 21 Jun 2026 · 13 likes Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that…
-
Publication patterns in the BPC-157 literature, examined Replied, post #10 · Compounds › Repair & healing peptides · 9 Jun 2026 · 16 likes Worth separating two things that post #6 runs together. TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The…
-
[2026 update] Regional warehouse stock versus direct despatch Replied, post #92 · Sourcing › Logistics · 5 Jun 2026 · 10 likes Cold packs and temperature control: inclusion of cold packs at despatch is standard. Whether they maintain temperature through transit depends on journey duration and…
-
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one… Replied, post #8 · Compounds › Retatrutide · 2 Jun 2026 · 5 likes Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps. The step sizes are documented and they may or may not…
-
Reading a trial's population section before its results Replied, post #60 · Evidence › Trials · 27 May 2026 · 0 likes The estimand: what the trial set out to estimate. Two trials can be identical in structure but estimate different things by using different handling rules for people…
-
Historical amylin analogues and what happened to them Replied, post #9 · Compounds › Cagrilintide & amylin analogues · 17 May 2026 · 22 likes post #8 is right about the mechanism and I think understates the practical bit. Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct…
-
Splitting an overlong document into two Replied, post #18 · Documentation › Wiki requests · 10 May 2026 · 3 likes Format suggestions: if you think a maintained page could be clearer in its presentation (different section structure, different examples, added graphics) suggest the…
-
Forced degradation studies: designing one that is informative Replied, post #50 · Analytics › Method validation · 6 May 2026 · 3 likes Worth separating two things that post #46 runs together. Transfer between laboratories: a method can be transferred from one lab to another, but the receiving lab needs…
-
Why the timeline is on the right and not the left — what changed since Replied, post #28 · Meta › Site feedback · 29 Apr 2026 · 9 likes Moderation decisions: if you disagree with a moderation decision, raising it here gives it visibility. Staff will reconsider if you make a substantive case.
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #4 · Evidence › Journal club · 16 Apr 2026 · 0 likes On the opening post — agreed on the reasoning, with one qualification. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down…
-
Prescription portability between countries Replied, post #5 · Access › International · 9 Apr 2026 · 0 likes I read post #3 twice before replying, because I had assumed the opposite. Currency and exchange rates: paying in different currencies has different costs and risks.…
-
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #23 · Lounge › Introductions · 9 Mar 2026 · 0 likes Ongoing: you can post multiple introductions over time. If you return after a long break, reintroducing yourself is fine.
-
Mass error in ppm: the arithmetic and the caveat Replied, post #7 · Analytics › Mass spectrometry · 11 Feb 2026 · 29 likes Desalting before analysis: some samples need desalting to remove salts that suppress the peptide signal. Report whether desalting was used, because it can affect the…
-
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #84 · Access › Pricing · 9 Feb 2026 · 19 likes Cost per milligram is the only comparison that survives format differences, but even then it needs care. A pen and a vial are not the same product and cannot be…
-
Waist circumference technique and its repeatability Replied, post #42 · Outcomes › Progress reports · 23 Jan 2026 · 31 likes Protein intake and resistance training: both self-reported and therefore optimistic in most reports. Recording them anyway creates a record you can look back on.
-
The most common factual error about semaglutide on the internet — what changed since Replied, post #5 · Compounds › Semaglutide · 10 Jan 2026 · 11 likes The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives you are not approaching steady state yet, which is…
-
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #40 · Sourcing › Red flags · 6 Jan 2026 · 4 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Reading an interaction checker output critically Replied, post #78 · Practice › Interactions · 29 Dec 2025 · 32 likes post #77 is right about the mechanism and I think understates the practical bit. For anyone arriving from a search: the marked solution above is the direct answer, and…
-
Reading SURMOUNT-1 without the press release Replied, post #79 · Compounds › Tirzepatide · 26 Nov 2025 · 7 likes The 2.5 mg starting dose is not a therapeutic dose in the sense that weight loss is minimal at that dose. It is a tolerance-testing dose. Confusing the purpose of a…
-
[2026 update] How much of the diluent volume the powder itself displaces Replied, post #80 · Practice › Reconstitution · 26 Nov 2025 · 4 likes The decimal-point error: computing 5 mg / 2 mL as 0.25 mg/mL instead of 2.5 mg/mL is the most common arithmetic error in this subcategory. The habit that catches it:…
-
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Replied, post #46 · Sourcing › Regulatory · 24 Nov 2025 · 33 likes Worth separating two things that post #42 runs together. Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a…
-
Coming back to: Injection-site reactions: describing them precisely enough to be useful Replied, post #8 · Practice › Side effects · 22 Nov 2025 · 18 likes Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during…
-
Availability by country, dated, with primary sources Replied, post #69 · Access › International · 21 Nov 2025 · 22 likes Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.
-
How to read a phase 2 result without treating it as a phase 3 result — what changed since Replied, post #13 · Compounds › Retatrutide · 31 Oct 2025 · 5 likes What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate…
-
When to stop reading forums, including this one Replied, post #40 · Wellbeing › Mental health · 23 Oct 2025 · 10 likes I read post #38 twice before replying, because I had assumed the opposite. Social and relationship impacts: weight change affects how others perceive and interact with…
-
Second pass at: How to ask a question when you cannot say why you are asking it Replied, post #23 · Start Here › How to Ask · 15 Oct 2025 · 4 likes On post #19 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…
-
Payment method and the leverage it gives you, ranked Replied, post #67 · Sourcing › Payments · 24 Sep 2025 · 10 likes post #66 is right about the mechanism and I think understates the practical bit. Currency conversion: payment in your local currency often involves a conversion fee.…
-
Can a home kit substitute for a laboratory report? A careful no Replied, post #16 · Analytics › Home & field testing · 22 Sep 2025 · 25 likes post #15 answers the question as asked. The question underneath it is different. Colorimetric tests: colour intensity correlates with concentration, but the…
-
Why catalogue breadth is not evidence of anything — what changed since Replied, post #40 · Compounds › Other compounds · 9 Sep 2025 · 0 likes Picking up post #37: that is the part I would want checked first. I disagree with the reply above, and I think the disagreement is substantive rather than…
-
Aggregated purity results across four services, with caveats — a second dataset Replied, post #54 · Data & Tools › Datasets · 8 Sep 2025 · 12 likes On post #50 — agreed on the reasoning, with one qualification. Combining data from different sources: datasets from this site are not directly comparable to published…
-
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #80 · Compounds › Retatrutide · 5 Sep 2025 · 0 likes post #79 answers the question as asked. The question underneath it is different. Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is…
-
Confounding by indication, explained with a concrete example Replied, post #6 · Evidence › Study critique · 31 Aug 2025 · 0 likes I read post #4 twice before replying, because I had assumed the opposite. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so…
-
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #40 · Evidence › Journal club · 23 Aug 2025 · 2 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
What published stability data actually covers, and what it does not — what changed since Started this topic · Practice › Storage & stability · 16 Aug 2025 · 6 likes What published stability data actually covers, and what it does not — what changed since — that is the question, and I have not found it answered plainly anywhere I…
-
How to research a compound with no human data without deceiving yourself Replied, post #60 · Compounds › Other compounds · 2 Aug 2025 · 6 likes post #59 is right about the mechanism and I think understates the practical bit. How to research a compound with no human data: mechanistic plausibility is one input.…
-
The CagriSema phase 2 paper and what a fixed combination buys Replied, post #76 · Compounds › Cagrilintide & amylin analogues · 30 Jul 2025 · 18 likes The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.
-
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #64 · Evidence › Journal club · 4 Jul 2025 · 31 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Gauge and length selection for subcutaneous injection Replied, post #6 · marked as the solution · Devices › Syringes & needles · 20 Jun 2025 · 15 likes Syringe barrel size: common sizes are 0.3 mL, 0.5 mL, and 1.0 mL. Smaller barrels are more legible for small doses. Larger barrels hold larger volumes. Choose based on…
-
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #29 · Data & Tools › Calculators · 19 Jun 2025 · 26 likes I read post #27 twice before replying, because I had assumed the opposite. Precision and significant figures: the calculators do not round to match your input…
-
Second pass at: Reading a combination trial: attributing effect to components Replied, post #26 · Compounds › Cagrilintide & amylin analogues · 10 Jun 2025 · 9 likes Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate…
-
Follow-up: The decimal-point error, and the habit that catches it Replied, post #6 · Practice › Reconstitution · 31 May 2025 · 0 likes Coming back to post #4, because the follow-up matters more than the original answer. A vial that will not fully dissolve: check in order: is the diluent genuinely room…
-
Half-life, steady state, and accumulation worked through Replied, post #35 · Pharmacology › Pharmacokinetics · 28 May 2025 · 0 likes Picking up post #32: that is the part I would want checked first. For anyone arriving from a search: the marked solution above is the direct answer, and the replies…
-
Follow-up: Documentation that appears only after payment Replied, post #76 · Sourcing › Red flags · 14 May 2025 · 1 like post #75 is right about the mechanism and I think understates the practical bit. Unresponsiveness: a supplier that does not reply to reasonable requests for…
-
Cost per milligram, computed honestly across formats — the long version Replied, post #91 · Access › Pricing · 7 May 2025 · 5 likes Price variation between pharmacies: identical prescriptions can cost different amounts at different pharmacies because pharmacies negotiate individually with insurers…
-
Carryover and the ghost peak from last week's standard Replied, post #88 · Analytics › HPLC & UHPLC · 12 Apr 2025 · 4 likes Method validation is the demonstration that a method can separate the compound from its degradation products and impurities reliably. A method that cannot resolve an…
-
Carryover and the ghost peak from last week's standard Replied, post #63 · Analytics › HPLC & UHPLC · 9 Apr 2025 · 5 likes Reversed-phase separates on hydrophobicity. A peptide is retained on a non-polar stationary phase and eluted by increasing organic solvent. For peptides the mobile…
-
Follow-up: What other technical communities get right that we do not Replied, post #54 · Lounge › Off topic · 31 Mar 2025 · 14 likes Science communication: if you come across an interesting science paper or article about peptides or metabolism, sharing it and discussing the idea is on-topic.
-
Reconstituting a multi-strength kit without mixing yourself up Replied, post #49 · Practice › Reconstitution · 26 Mar 2025 · 21 likes A vial that will not fully dissolve: check in order: is the diluent genuinely room temperature (some preservatives crystallise in cold), is the vial being warmed gently…
-
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #46 · Compounds › Semaglutide · 20 Mar 2025 · 0 likes Coming back to post #44, because the follow-up matters more than the original answer. On alcohol: the labelling does not contraindicate it, but it raises gastric…
-
Maintainer handover: how it works Replied, post #34 · Meta › Wiki maintenance · 15 Mar 2025 · 1 like post #33 answers the question as asked. The question underneath it is different. Revision disputes: if you disagree with an edit a maintainer made, discussing it here…
-
Checking someone else's arithmetic: a worked example thread Replied, post #28 · Practice › Reconstitution · 10 Mar 2025 · 20 likes Osmolarity and reconstitution: the osmolarity of the reconstituted solution affects comfort on injection. Isotonic solutions (close to blood osmolarity) are less…
-
Second pass at: Regression to the mean in progress reports Replied, post #66 · Research Methods › Statistics · 24 Feb 2025 · 3 likes Power and sample size: a study might be too small to detect a real effect (low power). Sample size calculations help determine how many participants are needed to…
-
When to suspect the method rather than the sample Replied, post #87 · Analytics › Method validation · 24 Feb 2025 · 6 likes Picking up post #84: that is the part I would want checked first. Why two laboratories may disagree: after validating the same method, they may still report different…
-
A page that has drifted out of date and needs a maintainer Replied, post #66 · Documentation › Wiki requests · 19 Feb 2025 · 8 likes Scope creep: if you think a page is attempting too much and should be split into multiple pages, that is a reasonable suggestion.
-
Protein density versus volume when you cannot eat much Replied, post #25 · Nutrition & Training › Protein & intake · 27 Jan 2025 · 31 likes Micronutrition alongside protein: eating protein foods that are also good sources of micronutrients (iron, B vitamins, zinc) solves two problems at once.
-
The topic list is dense — is that deliberate? Replied, post #85 · Meta › Site feedback · 19 Jan 2025 · 5 likes Guideline clarity: if the guidelines are unclear or seem to be applied inconsistently, post the specific situation so staff can clarify or reconsider.
-
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #4 · Compounds › Tirzepatide · 16 Jan 2025 · 6 likes post #3 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather than…
-
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #2 · Compounds › Retatrutide · 30 Dec 2024 · 26 likes On the opening post — agreed on the reasoning, with one qualification. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down…
-
[2026 update] Step therapy requirements and how to satisfy them Replied, post #93 · Access › Insurance & coverage · 29 Dec 2024 · 30 likes Picking up post #90: that is the part I would want checked first. Denial letters: the stated reason tells you exactly what to submit next. A denial is not final; it is…
-
Coming back to: When to suspect the method rather than the sample Replied, post #130 · Analytics › Method validation · 25 Dec 2024 · 1 like Why two laboratories may disagree: after validating the same method, they may still report different purity on the same sample due to integration differences, column…
-
Journal club: SURMOUNT-1, read without the press release Replied, post #19 · Evidence › Journal club · 26 Nov 2024 · 0 likes SURPASS-2 (N Engl J Med 2021): Direct comparison of tirzepatide with semaglutide 1.0 mg. The 1.0 mg dose is not the highest available, which is the central and…
-
EMA product information as a primary source — does this still hold? Replied, post #43 · Regional › European Union · 16 Nov 2024 · 18 likes Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.
-
Here for the analytics and not much else — one year on Replied, post #4 · Lounge › Introductions · 7 Nov 2024 · 28 likes Worth separating two things that post #2 runs together. Welcome: the response to introductions is usually welcome. People will reply to introduce themselves back or to…
-
Time to steady state after a dose increase Replied, post #160 · Pharmacology › Pharmacokinetics · 6 Nov 2024 · 0 likes SNAC (the oral bioavailability enhancer): sodium N-(8-[2-hydroxybenzoyl]amino) caprylate transiently raises gastric pH and promotes absorption. Without it, oral…
-
Time to steady state after a dose increase Replied, post #18 · Pharmacology › Pharmacokinetics · 2 Nov 2024 · 24 likes Individual variation: people vary in how quickly they absorb, distribute, metabolise, and excrete these compounds. That variation is partly genetic and partly due to…
-
Second pass at: Food noise reducing and the disorientation that can follow Replied, post #6 · Wellbeing › Mental health · 26 Sep 2024 · 6 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
What a stability-indicating method is and how you demonstrate one — one year on Replied, post #38 · Analytics › Method validation · 23 Sep 2024 · 0 likes On post #34 — agreed on the reasoning, with one qualification. Limits of detection and quantitation: LOD is the lowest concentration that produces a signal above…
-
Meeting a protein target on a suppressed appetite — one year on Replied, post #20 · Nutrition & Training › Protein & intake · 21 Sep 2024 · 14 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
[2026 update] People with a low starting BMI: where the evidence stops Replied, post #21 · Clinical › Special populations · 7 Sep 2024 · 24 likes Disordered eating history: a history of anorexia nervosa, bulimia, or other eating disorders changes the risk-benefit calculation because appetite suppression might…
-
Blind submission and why it changes minds Replied, post #26 · Sourcing › Independent verification · 31 Jul 2024 · 10 likes Janoshik Analytical: chromatographic purity and mass-spectrometric identity on submitted samples. Reports are issued with the analytical method stated and a…
-
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #69 · Practice › Dosing & titration · 8 Jul 2024 · 25 likes This follows post #66 rather than contradicting it. Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure,…